(FTV) Fortive Corporation BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(FTV) Fortive Corporation Bundle
Download Your Competitive Advantage
This Fortive Corporation BCG Matrix helps you see how the company’s products or business units are positioned across the classic Stars, Cash Cows, Question Marks, and Dogs framework. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Fluke electrical test and calibration
Fluke electrical test and calibration is one of Fortive Corporation’s strongest franchises, with heavy use in maintenance, utilities, and factory uptime. It fits Star status because demand is tied to electrification, data-center buildout, and strict compliance testing, while the brand keeps a high share in a growing market. Industry demand is still rising, with the global test and measurement market projected to expand at about 5%-7% CAGR through 2026.
Accruent asset lifecycle software
Accruent is Fortive Corporation’s facilities and asset lifecycle software business, built on a large installed base and recurring subscriptions. The move from on-premise tools to cloud delivery should keep demand growing through 2025, especially as customers want lower IT upkeep and easier upgrades. It stays a Stars-style contender, but Fortive still needs steady product investment to defend share and lift ARR.
Intelex EHSQ software
Intelex EHSQ software is a Star because it supports environmental, health, safety, and quality compliance workflows where regulation keeps tightening. Its scale gives Fortive a strong base, but holding share still needs steady sales and product spend. ESG reporting demands keep the addressable market growing, so this platform can stay a high-growth asset if Fortive keeps investing.
Tektronix test and measurement
Tektronix test and measurement is a strong Star in Fortive Corporation’s BCG Matrix because it serves semiconductor, electronics validation, and advanced R and D labs. Demand is rising with AI chips, higher-speed data links, and complex power electronics, all of which need precise oscilloscopes, signal analyzers, and validation tools.
- Premium brand in a growing niche
- AI chip testing lifts demand
- Speed and power design complexity grows
- R and D labs need high-end validation
ASP sterilization systems
ASP sterilization systems is a strong Star for Fortive Corporation because it sits in low-temperature sterilization and infection prevention, where hospitals need reliable uptime and strict compliance. The brand benefits from steady demand tied to operating room throughput, but it still needs product refreshes and tight service execution to defend share.
- Strong brand in hospital sterilization
- Demand linked to compliance and throughput
- Needs ongoing product and service investment
Fortive’s Star Assets Tap Electrification, AI, and Compliance Growth
Fortive Corporation’s Stars are the growth engines: Fluke, Tektronix, Accruent, Intelex, and ASP. They sit in expanding niches tied to electrification, AI hardware testing, cloud migration, ESG compliance, and hospital sterilization. The test and measurement market is still projected at about 5% to 7% CAGR through 2026, which supports these assets.
| Asset | Star driver |
|---|---|
| Fluke | Uptime, electrification |
| Tektronix | AI chip testing |
What is included in the product
Detailed Word Document
Fortive BCG Matrix overview: maps its businesses into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
Quickly maps Fortive businesses into BCG quadrants to simplify portfolio decisions.
Reference Sources
Fortive Corporation Reference Sources provide a credible audit trail that speeds due diligence and supports faster, better decisions.
Cash Cows
Gordian construction cost data
Gordian supports construction estimating, procurement, and facilities planning, and Fortive’s 2025 filings still show it as a sticky, repeat-use software and data business. Its mature customer base and workflow lock-in help drive steady cash with low incremental capex, which fits the Cash Cow profile. In BCG terms, the goal is harvest cash, not heavy growth spend.
ServiceChannel facilities workflow
ServiceChannel fits Fortive Corporation’s cash cow bucket because it ties facilities teams to service providers and work orders through a sticky subscription model. Once embedded, these workflows are hard to rip out, so retention tends to stay high and sales turn into recurring cash rather than fast growth. In a mature FM software market, that makes ServiceChannel a steady cash generator, not a sprint story.
Landauer radiation monitoring
Landauer radiation monitoring is a classic cash cow: it provides dosimetry and compliance services to healthcare and industrial clients, and the recurring badge, reporting, and regulatory work keeps revenue steady. In Fortive Corporation’s 2025 profile, this kind of low-growth, high-repeat business supports reliable cash flow even without rapid expansion.
Gems and Setra sensors
Gems and Setra sensors are classic cash cows in Fortive Corporation’s BCG mix: they sell pressure, level, and sensing products into industrial and OEM channels, where demand is mature and tied to installed equipment and replacement cycles. That makes sales steadier than growth brands, and the scale of the installed base helps support strong, recurring cash flow.
- Industrial and OEM demand stays replacement-led.
- Installed base drives repeat orders.
- Scale supports margin and cash generation.
Qualitrol grid monitoring
Qualitrol supports transformer and grid monitoring for power infrastructure, so demand ties to utility reliability spending, not fast unit growth. In Fortive Corporation's BCG Matrix, that makes it a Cash Cow: steady installed-base sales, long product life, and recurring service work. Utility assets can stay in service for 30+ years, which supports slow but durable demand.
- Reliability-led utility purchases
- Long asset life, stable demand
- Low-growth, cash-generating niche
Fortive’s Cash Cows: Sticky Businesses That Keep Cash Flowing
Fortive Corporation’s Cash Cows are mature, installed-base businesses that turn repeat demand into steady cash, led by Gordian, ServiceChannel, Landauer, Gems/Setra, and Qualitrol. In 2025 filings, their value came from sticky workflows, replacement-led orders, and low capital needs, not high growth. That makes them cash generators the company can harvest while funding bets elsewhere.
| Business | Cash Cow driver |
|---|---|
| Gordian | Recurring software use |
| ServiceChannel | Sticky FM subscriptions |
| Landauer | Compliance renewals |
| Gems/Setra | Replacement demand |
Full Version Awaits
Fortive Corporation Reference Sources
The Fortive Corporation BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No mockups, no watered-down version—just the full, professionally formatted file. It’s ready to download, review, and use right away for strategic analysis. What you preview is exactly what you get.
Dogs
Pruftechnik machine alignment
Pruftechnik machine alignment fits Fortive Corporation's Dogs side of the BCG Matrix: it serves a narrow industrial maintenance niche in alignment and condition-monitoring tools, but it does not match the scale of Fortive's software and test platforms. Fortive reported $6.2 billion of 2024 revenue, and this business is a small slice of that base. In a competitive, low-volume market, it looks like a hold, not a growth engine.
Pacific Scientific legacy motion control
Pacific Scientific is a legacy motion-control brand inside Fortive Corporation, and its end markets are mature and crowded with larger automation rivals. Fortive’s 2025 revenue was about $6.2 billion, so this unit is a small, low-growth piece with limited leverage. In BCG terms, it fits Dogs: weak growth, modest strategic fit, and low priority for fresh capital.
Anderson-Negele sanitary sensors
Anderson-Negele sells sanitary process sensors for food, beverage, and bioprocessing, a niche that is steady but not a fast-growth driver. Fortive reported about $6.2 billion of revenue in 2024, while Anderson-Negele’s stand-alone revenue is not disclosed, so its share appears far narrower than Fortive’s core franchises. That profile fits a Dog more than a growth leader.
Hengstler-Dynapar encoders
Hengstler-Dynapar fits Fortive’s Dogs bucket: it serves encoders, counters, and industrial measurement niches, but the markets are fragmented and price competitive, so growth and margin expansion stay limited.
The line can still generate cash, yet it does not look like a priority growth platform for Fortive.
- Fragmented niche end markets
- Heavy price pressure
- Cash generative, low growth
- Weak fit for priority investment
Fluke Biomedical legacy testers
Fluke Biomedical legacy testers fit Fortive’s Dogs bucket: they serve a mature installed base in healthcare equipment testing and calibration, but the growth rate trails software-led assets. In 2025, Fortive’s mix still leaned toward higher-growth digital and connected offerings, while legacy test tools stayed tied to replacement demand and regulated service cycles.
- Low-growth, mature end market
- Installed base supports repeat sales
- Lower priority versus software assets
This makes Fluke Biomedical more of a cash-and-maintenance business than a growth engine, so BCG logic points to harvest or hold.
Fortive’s Legacy Niche Brands: Low Growth, Cash-Generating Dogs
Fortive Corporation's Dogs are mostly legacy, niche tools with weak growth and limited scale. Fortive reported about $6.2 billion of 2025 revenue, but brands like Pruftechnik, Pacific Scientific, Anderson-Negele, Hengstler-Dynapar, and Fluke Biomedical sit in mature markets where replacement demand, not expansion, drives sales. They still throw off cash, but they are low-priority for new capital.
| Unit | BCG view | Why |
|---|---|---|
| Legacy niche brands | Dogs | Low growth, small scale, cash focus |
Question Marks
Censis instrument tracking
Censis fits a Question Mark: it serves hospital instrument tracking and sterile processing, a niche with clear demand as hospitals digitize workflows. But its share is still far below large enterprise platforms like Epic and Oracle Health, so the upside is real only if Fortive keeps funding product and sales.
In a market where U.S. healthcare IT spending keeps rising and hospitals still track assets with mixed manual and digital systems, Censis can win on workflow depth. If growth stalls, it can slip toward a Dog, so the business needs steady investment in integration, implementation, and customer retention.
Censitrac inventory software
Censitrac supports surgical inventory management and traceability, so it fits a Question Mark in Fortive Corporation’s BCG matrix: the market is attractive, but the share is still small. Hospitals are under pressure from compliance and labor costs, which helps the category grow, yet Fortive has not disclosed Censitrac revenue, so scale is unclear. The move now is to win share fast or it can stay a niche tool.
Evotech sterile processing workflow
Evotech supports operating-room and sterile processing efficiency by automating tray tracking, workflow steps, and reprocessing visibility, which fits the shift toward software-led hospital operations. In Fortive Corporation’s BCG Matrix, it stays a Question Mark because adoption is still early, so scale is not yet proven. The addressable market is still growing as hospitals favor subscription software and automation over manual processes.
Invetech healthcare development services
Invetech, Fortive Corporation’s healthcare development services arm, fits a Question Mark: medtech product development can grow fast, but project work is lumpy and hard to scale. Fortive reported $6.2 billion of 2024 revenue, and only focused investment will show whether Invetech can win durable share in a market where medtech R&D spending stays high. The business has upside, but it still needs proof.
High-growth medtech demand
Project revenue is uneven
Selective investment is key
Share gains are not proven
Connected healthcare analytics
Fortive Corporation's connected healthcare analytics is still a Question Mark: hospital digital spending keeps rising, but these software and service bundles have not yet built dominant share. The addressable market is expanding as systems push electronic records, workflow data, and device connectivity into one stack, so the growth runway is real.
- High growth, weak share
- Invest or exit
- Digitization supports demand
In BCG terms, the business needs more capital and tighter execution to win share, or it should be pruned before returns stay thin.
Fortive’s Question Marks Need Faster Scale
Censis, Censitrac, Evotech, Invetech, and connected healthcare analytics are Question Marks: demand is growing, but share is still unproven. Fortive needs faster sales, tighter integration, and more capital, or these units can stay small and drag returns.
| Unit | BCG | Signal |
|---|---|---|
| Censis | Question Mark | Niche, low share |
| Invetech | Question Mark | High growth, lumpy |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.